30.1 C
Delhi

Aurobindo unit, Evive Biotech ink licensing pact to commercialise CIN treatment product in US

Published:


Aurobindo unit, Evive Biotech ink licensing pact to commercialise CIN treatment product in US The product, a novel dimeric G-CSF long-acting fusion protein without pegylation, is currently under late-stage review by the US Food and Drug Administration for chemotherapy-induced neutropenia (CIN).

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Recent articles